Trial Profile
A Randomised, Double-blind, Single-centre, Placebo-controlled, Ascending Single s.c. Dose, Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs HS 20004 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
- 28 Apr 2016 New trial record